glp1
CagriSema tracker
Educational reference for CagriSema. Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
—
Tmax
—
Category
glp1
Also known as: cagri-sema, cagrilintide-semaglutide
CagriSema is an investigational cagrilintide plus semaglutide combination.
Mechanism
A fixed-ratio combination of cagrilintide (an amylin analogue) and semaglutide (a GLP-1 receptor agonist).
Research summary
Investigational combination studied in the REDEFINE program for weight management and in type 2 diabetes. Regulatory status should be verified against current FDA announcements.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- CagriSema phase 3 (REDEFINE) publications · peer-reviewed clinical trial series (2025)It is a combination; PK is that of its components. See the cagrilintide and semaglutide entries.
TrackPep est un outil de suivi. Il enregistre ce que vous saisissez et ne recommande ni ne calcule jamais de quantités.